Investigational therapy ulefnersen demonstrated statistically significant improvements in functional impairment and survival, marking a potential breakthrough for a rare and rapid form of ALS.
No benefit seen in primary end point of median clonal growth rate, but benefits seen in terms of secondary outcomes.